Association of cardiovascular factors and alzheimer's disease plasma amyloid-β protein in subjective memory complainers

Journal of Alzheimer's Disease

Volumn 17, Issue 2, 2009, Pages 305-318

  Bates, Kristyn A ^a,b,c   Sohrabi, Hamid R ^b,c   Rodrigues, Mark ^a,b   Beilby, John ^c   Dhaliwal, Satvinder S ^d   Taddei, Kevin ^a,b,c   Criddle, Arthur ^e   Wraith, Megan ^e   Howard, Matthew ^a,b,c   Martins, Georgia ^a,b,c   Paton, Athena ^b,c   Mehta, Pankaj ^f   Foster, Jonathan K ^a,b   Martins, Ian J ^a,b,c   Lautenschlager, Nicola T ^c,g,h   Mastaglia, Frank L ^c   Laws, Simon M ^a,b,i   Gandy, Samuel E ^j   Martins, Ralph N ^a,b,c  

^a EDITH COWAN UNIVERSITY   (Australia)

^b HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e Hollywood Specialist Centre   (Australia)

^f NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Aging; Amyloid ; Apolipoprotein E; Cholesterol; Dementia; High density lipoprotein

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DISEASE ASSOCIATION; FEMALE; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; PRIORITY JOURNAL;

EID: 67849089088     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1050     Document Type: Article

References (117)

1. Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890.
2. Glenner GG, Wong CW (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122, 1131-1135.
3. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4, 2757-2763.
4. Storey E, Cappai R (1999) The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol Appl Neurobiol 25, 81-97.
5. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472.
6. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-1981.
7. Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10, 14851494.
8. Carr DB, Goate A, Phil D, Morris JC (1997) Current concepts in the pathogenesis of Alzheimer's disease. Am J Med 103, 3S-10S.
9. Roses AD (1997) Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis 4, 170-185.
10. Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ, Berry-Kravis E, Bienias JL (2003) Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 60, 246-252.
11. Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, Hebert LE, Aggarwal N, Beckett LA, Joglekar R, Berry-Kravis E, Schneider J (2003) Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 60, 185-189.
12. Laws SM, Hone E, Gandy S, Martins RN (2003) Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 84, 1215-1236.
13. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L (2004) APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol 61, 1930-1934.
14. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
15. Mahley RW, Nathan BP, Pitas RE (1996) Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Ann NY Acad Sci 177, 139-145.
16. Weisgraber KH (1994) Apolipoprotein E: structure-function relationships. Adv Protein Chem 45, 249-302.
17. Comijs HC, Deeg DJ, Dik MG, Twisk JW, Jonker C (2002) Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics. A 6-year follow-up study. J Affect Disord 12, 157-165.
18. Minett TS, Da Silva RV, Ortiz KZ, Bertolucci PH (2007) Subjective memory complaints in an elderly sample: a cross- sectional study. Int J Geriatr Psychiatry 23, 49-54.
19. Reid LM, Maclullich AM (2006) Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord 22, 471-485.
20. Mol M, Carpay M, Ramakers I, Rozendaal N, Verhey F, Jolles J (2007) The effect of perceived forgetfulness on quality of life in older adults; a qualitative review. Int J Geriatr Psychiatry22, 393-400.
21. Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B (1999) Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 156, 531-537.
22. Jonker C, Geerlings MI, Schmand B (2000) Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 15, 983-991.
23. Jorm AF, Christensen H, Korten AE, Jacomb PA, Henderson AS (2001) Memory complaints as a precursor of memory impairment in older people: a longitudinal analysis over 7-8 years. Psychol Med 31, 441-449.
24. Palmer K, Backman L, Winblad B, Fratiglioni L (2003) Detection ofAlzheimer's disease and dementia in the preclinical phase: population based cohort study. BMJ 326, 245.
25. Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA (2006) Memory complaints are related to Alzheimer disease pathology in older persons. Neurology 61, 1581-1585.
26. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11, 721-736.
27. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA, Laakso M, Kuusisto J (2006) Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 61, 843-847.
28. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163, 1524-1528.
29. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Jr., Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330, 1360.
30. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk ofdementia and Alzheimer disease. Arch Neurol 62, 1556-1560.
31. Gustafson D, Lissner L, Bengtsson C, Bjorkelund C, Skoog I (2004) A 24-year follow-up ofbody mass index and cerebral atrophy. Neurology 63, 1876-1881.
32. Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains ofrabbits with dietary cholesterol. Exp Neurol 126, 88-94.
33. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW, Flood DG (1998) Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem 213, 16576-16582.
34. George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G, Masters CL, Li QX (2004) APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis 16, 124132.
35. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels ofAlzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98, 5856-5861.
36. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model ofAlzheimer's disease. Neurobiol Dis 8, 890-899.
37. Hartmann T (2001) Cholesterol, A beta and Alzheimer's disease. Trends Neurosci 24, S45-48.
38. Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C, Svetlik D (2003) Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 60, 510-515.
39. Wolozin B (2004) Cholesterol and the biology of Alzheimer's disease. Neuron 41, 7-10.
40. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155, 487-495.
41. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90, 8098-8102.
42. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, et al. (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94, 860-869.
43. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN (1997) Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 68, 721-725.
44. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U SA 97, 2892-2897.
45. Hone E, Martins IJ, Fonte J, Martins RN (2003) Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 5, 1-8.
46. Lovestone S, Anderton BH, Hartley C, Jensen TG, Jorgensen AL (1996) The intracellular fate ofapolipoprotein E is tau dependent and apoe allele-specific. Neuroreport 7, 1005-1008.
47. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 156, 951-964.
48. McGeer PL, Walker DG, Pitas RE, Mahley RW, McGeer EG (1997) Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta- amyloid protein activation of complement in vitro. Brain Res 749, 135-138.
49. Hone E, Martins IJ, Jeoung M, Ji TH, Gandy SE, Martins RN (2005) Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 7, 303-314.
50. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 5, 655-660.
51. Adlard PA, Perreau VM, Pop V, Cotman CW (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 25, 4217-4221.
52. Weuve J, Kang JH, Manson JE, Breteler MM, Ware JH, Grodstein F (2004) Physical activity, including walking, and cognitive function in older women. JAMA 292, 1454-1461.
53. van Gelder BM, Tijhuis MA, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D (2004) Physical activity in relation to cognitive decline in elderly men: the FINE Study. Neurology 63, 2316-2321.
54. Kramer AF, Colcombe SJ, McAuley E, Scalf PE, Erickson KI (2005) Fitness, aging and neurocognitive function. Neurobiol Aging 26 Suppl 1, 124-127.
55. Lautenschlager NT, Almeida OP (2006) Physical activity and cognition in old age. Curr Opin Psychiatry 19, 190-193.
56. Clarnette RM, Almeida OP, Forstl H, Paton A, Martins RN (2001) Clinical characteristics ofindividuals with subjective memory loss in Western Australia: results from a cross-sectional survey. Int J Geriatr Psychiatry 16, 168-174.
57. Lautenschlager NT, Wu JS, Laws SM, Almeida OP, Clarnette RM, Joesbury K, Wagenpfeil S, Martins G, Paton A, Gandy SE, Forstl H, Martins RN (2005) Neurological soft signs are associated with APOE genotype, age and cognitive performance. Alzheimers Dis 7, 325-330.
58. Laws SM, Clarnette RM, Taddei K, Martins G, Paton A, Hallmayer J, Almeida OP, Groth DM, Gandy SE, Forstl H, Martins RN (2002) APOE-epsilon4 and APOE - 491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 7, 768-775.
59. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
60. Roth M, Huppert FA, Mountjoy CQ, Tym E (1988) CAMDEX The Cambridge Examination for Mental Disorders of the Elderly Revised, Cambridge University Press.
61. Delis DC, Freeland J, Kramer JH, Kaplan E (1988) Integrating clinical assessment with cognitive neuroscience: construct validation of the California Verbal Learning Test. J Consult Clin Psychol 56, 123-130.
62. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149, 698-709.
63. Schofield PW, Jacobs D, Marder K, Sano M, Stern Y (1997) The validity of new memory complaints in the elderly. Arch Neurol 54, 756-759.
64. Abdulrab K, Heun R (2008) Subjective Memory Impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria. Eur Psychiatry 23, 321-330.
65. Mattos P, Lino V, Rizo L, Alfano A, Araujo C, Raggio R (2003) Memory complaints and test performance in healthy elderly persons. Arq Neuropsiquiatr 61, 920-924.
66. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17, 37-49.
67. Spielberger CD, Gorsuch RL, Lushene RD, Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory, Consulting Psychologists Press, Palo Alto.
68. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. Lipid Res 31, 545-548.
69. Mehta PD, Dalton AJ, Mehta SP, Kim KS, Sersen EA, Wisniewski HM (1998) Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241, 13-16.
70. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105.
71. Craig SR, Amin RV, Russell DW, Paradise NF (2000) Blood cholesterol screening influence of fasting state on cholesterol results and management of decisions. Gen Intern Med 15, 395-399.
72. Smith CC, Betteridge DJ (2004) Plasma beta-amyloid (A beta) 40 concentration, lipid status and age in humans. Neurosci Lett 367, 48-50.
73. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362.
74. Henderson VW (1997) Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 103, 11S-18S.
75. Bonithon-Kopp C, Scarabin PY, Darne B, Malmejac A, Guize L (1990) Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int Epidemiol 19, 42-48.
76. Qiu C, Winblad B, Fastbom J, Fratiglioni L (2003) Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology 61, 655-660.
77. Biessels GJ, Kappelle LJ (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33, 1041-1044.
78. Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA, Newton R, Gandy SE, Martins RN (2005) Plasma Abeta42 correlates positively with increased body fat in healthy individuals. Alzheimers Dis 8, 269-282.
79. Cereda E, Sansone V, Meola G, Malavazos AE (2007) Increased visceral adipose tissue rather than BMI as a risk factor for dementia. Age Ageing 36, 488-491.
80. Jagust W, Harvey D, Mungas D, Haan M (2005) Central obesity and the aging brain. Arch Neurol 62, 1545-1548.
81. Glodzik-Sobanska L, Reisberg B, De Santi S, Babb JS, Pirraglia E, Rich KE, Brys M, De Leon MJ (2007) Subjective memory complaints: presence, severity and future outcome in normal older subjects. Dement Geriatr Cogn Disord 24, 177-184.
82. Ponds RW, Commissaris KJ, Jolles J (1997) Prevalence and covariates of subjective forgetfulness in a normal population in The Netherlands. Int Aging Hum Dev 45, 207-221.
83. Jelicic M, Jonker C, Deeg DJ (1999) Do health factors affect memory performance in old age? Int Geriatr Psychiatry 14, 572-576.
84. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ (2008) Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 63, 609-618.
85. Rimajova M, Lenzo NP, Wu J-S, Bates KA, Campbell A, Dhaliwal SS, McCarthy M, Rodrigues M, Paton A, Rowe CC, Foster JK, Martins RN (2007) Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEeε4 carriers in the Australian population. J Alzheimers Dis 13, 137-146.
86. Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, McHugh TL, Mamourian AC (2006) Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 67, 834-842.
87. van der Flier WM, van Buchem MA, Weverling-Rijnsburger AW, Mutsaers ER, Bollen EL, Admiraal-Behloul F, Westendorp RG, Middelkoop HA (2004) Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. Neurol 251, 671-675.
88. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A (2007) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29, 1456-1465.
89. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844.
90. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725.
91. LaDu MJ, Lukens JR, Reardon CA, Getz GS (1997) Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. Neurosci Res 49, 9-18.
92. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-betapeptides. Nat Med 10, 719-726.
93. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 96, 1523315238.
94. Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIn- tosh TK, Holtzman DM (2002) Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. Neurosci 22, 10083-10087.
95. McNamara MJ, Gomez-Isla T, Hyman BT (1998) Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 55, 1001-1004.
96. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J (2004) Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62, 1977-1983.
97. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lam- pert HC, Drumm D, Roher AE (1998) Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252, 711-715.
98. Merched A, Xia Y, Visvikis S, Serot JM, Siest G (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21, 2730.
99. Raygani AV, Rahimi Z, Kharazi H, Tavil and H, Pourmotabbed T (2006) Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci Lett 408, 68-72.
100. Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG (2008) Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife. The Whitehall II study. Arterioscler Thromb Vasc Biol 28, 1557-1563.
101. Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breit- ner JCS, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB (2005) Serum cholesterol and risk of Alzheimer's disease. A community-based cohort study. Neurology 65, 1045-1050.
102. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59, 378-384.
103. Wolf H, Hensel A, Arendt T, Kivipelto M, Winblad B, Gertz HJ (2004) Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol 56, 745-748.
104. Olesen of, Dago L (2000) High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils. Biochem Bio-phys Res Commun 270, 62-66.
105. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357.
106. Koudinov AR, Berezov TT, Kumar A, Koudinova NV (1998) Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 210, 75-84.
107. Wilson LM, Pham CL, Jenkins AJ, Wade JD, Hill AF, Perugini MA, Howlett GJ (2006) High density lipoproteins bind Abeta and apolipoprotein C-II amyloid fibrils. J Lipid Res 41, 755-760.
108. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 211, 32916-32922.
109. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J (1996) Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Associations with high density lipoproteins. Biochem Biophys Res Commun 223, 592-597.
110. Cole GM, Beech W, Frautschy SA, Sigel J, Glasgow C, Ard MD (1999) Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro. J Neurosci Res 51, 504520.
111. Hirsch-Reinshagen V, Wellington CL (2007) Cholesterol metabolism, apolipoprotein E, adenosine triphosphate- binding cassette transporters, and Alzheimer's disease. Curr Opin Lipidol 18, 325-332.
112. Vaya J, Schipper HM (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem 102, 1727-1737.
113. Burkhardt MS, Foster JK, Laws SM, Baker LD, Craft S, Gandy SE, Stuckey BG, Clarnette R, Nolan D, Hewson-Bower B, Martins RN (2004) Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis 6, 221-228.
114. Podewils LJ, Guallar E, Kuller LH, Fried LP, Lopez OL, Carlson M, Lyketsos CG (2005) Physical Activity, APOE Genotype, and Dementia Risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 161, 639-651.
115. Gong JS, Morita SY, Kobayashi M, Handa T, Fujita SC, Yanagisawa K, Michikawa M (2007) Novel action of apolipoprotein E (ApoE): ApoE isof orm specifically inhibits lipid-particle-mediated cholesterol release from neurons. Mol Neurodegener 2,9.
116. Koldamova R, Staufenbiel M, Lefterov I (2005) Lack of AB- CA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280, 43224-43235.
117. Wollmer MA, Staffer JR, Lutjohann D, Tsolaki M, Iakovidou V, Hegi T, Pasch T, Jung HH, Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A (2003) ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24, 421-426.